HLB will launch its newly approved bile-duct drug alone into a US segment worth at most $81 million

Sizing the opportunity starts with the American Cancer Society's count of about 8,000 new bile duct cancer diagnoses a year in the United States ^[13]. Fortune Business Insights puts US spending on treating the disease at about $540 million this year ^[14], and the National Cancer Institute finds FGFR2 fusions in about 15% of intrahepatic cases ^[15]. Fifteen percent of $540 million is about $81 million ^[2], and 15% of 8,000 is 1,200 patients ^[3]. Both numbers are generous. The $540 million includes extrahepatic disease, where the 15% rate does not apply ^[14], and Rifiktu is only for patients who have already been treated and whose fusion has been confirmed ^[17].

Those patients can already get FGFR-targeted drugs approved before Rifiktu ^[17]. Its case against them is selectivity. The company says the drug binds FGFR2 for sustained inhibition while minimizing inhibition of FGFR1, 3 and 4, a design meant to reduce the side effects of hitting other receptors ^[9]. In the ReFocus trial, side effects were predictable and manageable through dose adjustment, according to the report ^[11]. Alison Schram, a medical oncologist at Memorial Sloan Kettering Cancer Center, said the drug showed durable treatment responses and manageable safety ^[12].

The deal terms are the better puzzle. The report does not break out the upfront payment inside the up-to-$500 million total ^[6]. Against the $81 million ceiling, $500 million is about six years of the entire FGFR2 share of US bile duct spending ^[4]. Payments on that scale look sized for a bigger drug than the one just approved. The European filing and the other-tumor trials ^[18] will decide whether HLB paid a sensible price.

Kim Dong-gun, Elevar's chief executive, said the company would supply Rifiktu to medical staff and patients as quickly as possible and would work to improve treatment for patients with limited options ^[19]. From there, selectivity may win second-line patients from the incumbents and push US sales toward the ceiling; uptake may stay slow and send HLB looking for a partner outside the US; or the other-tumor trials may widen the label until bile duct cancer is the smallest of Rifiktu's markets. I think the 21 months from licensing to approval ^[1] show Elevar can run an FDA review. I also think the US bile duct label alone is too small to account for a contract of up to $500 million. The counter-case is that a pool of at most 1,200 new patients a year ^[3] needs only a small sales effort, so even a modest revenue line could make money. That view wins if first-full-year US sales pass about $40 million, half the ceiling ^[5].